AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Beckershospitalreview

Published November 13, 2026 · Updated November 14, 2026

Mark Cuban's Cost Plus to develop US-made ibogaine in HHS push

Read the full story at Beckershospitalreview

Mark Cuban Cost Plus leads HHS-backed research to develop US-made ibogaine for PTSD and serious mental illnesses, focusing on safety and.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine